A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

NCT04748848 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed.

Conditions

Leukemia, Myeloid

Interventions

DRUG: CC-90011
DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Venetoclax
DRUG: CC-90011

Sponsor

Celgene